To unlock this feature and to subscribe to our weekly evidence emails, please create a FREE orthoEvidence account.

SIGNUP

Already Have an Account?

Loading...
Visit our Evidence-Based Covid-19 Website and Stay Up to Date with the latest Research.
Vol:5 Issue:9 Number:39 ISSN#:2564-2537
DOWNLOAD ESPAÑOL
Meta-Analysis
ACE Report #9096
Ace Report Cover Metabolic Disorders

Comparison of risedronate, alendronate, zoledronate, and ibandronate in those with low BMD


How to Cite

OrthoEvidence. Comparison of risedronate, alendronate, zoledronate, and ibandronate in those with low BMD. ACE Report. 2016;5(9):39. Available from: https://myorthoevidence.com/AceReport/Report/9096

Study Type:Meta analysis
OE Level Evidence:2
Journal Level of Evidence:N/A

Clinical effectiveness of bisphosphonates for the prevention of fragility fractures: A systematic review and network meta-analysis

Bone. 2016 Aug;89:52-8

Contributing Authors:
J Sanderson M Martyn-St James J Stevens E Goka R Wong F Campbell P Selby N Gittoes S Davis

Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here

Synopsis

A total of 27 randomized controlled trials were included in this network meta-analysis investigating the comparative efficacies of bisphosphonates - including alendronate, ibandronate, risedronate, and zoledronic acid - versus placebo or control in patients with low bone mineral density. All studied drugs demonstrated significant effects on vertebral fracture incidence and bone mineral density of ...

Ace Report Preview Image
CME Image

Continuing Medical Education Credits

You could be earning 0.5 CME credits for each report you read.

LEARN MORE
For Reprints and Permissions, click here

Please Login or Join to leave comments.